CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- 10-K Report Annual Report
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Material agreement · Results of operations · New debt or obligation
- 4 Grant or award CEO acquired 947 shares (grant or award)
- SEC STAFF LETTER Other SEC Staff Letter Redacted Exhibit
- 4 Grant or award CEO acquired 778 shares (grant or award)
- 4 Shares withheld for taxes SVP of Finance gave up 115 shares (to pay taxes)
- 4 Shares withheld for taxes CEO gave up 285 shares (to pay taxes)
- 4 Grant or award CEO acquired 877 shares (grant or award)
- SC 13G/A Stake Amended Statement of Ownership
- SEC STAFF LETTER Other SEC Staff Letter Redacted Exhibit
- 4 Grant or award CEO acquired 743 shares (grant or award)
- 4 Shares withheld for taxes CEO gave up 285 shares (to pay taxes)
- 4 Shares withheld for taxes SVP of Finance gave up 114 shares (to pay taxes)
- 8-K Event Material agreement · Executive or director change · Regulation FD disclosure
- SC 13D/A Stake Beneficial Ownership Report
- 4 Grant or award Director acquired 3,851 shares (grant or award)
- 4 Open-market buy 10% owner bought 400 shares at an average $2.82 ($1,127)
- 4 Open-market sale 10% owner sold 1,900 shares at an average $2.69 ($5,114)
- 4 Open-market buy 10% owner bought 299 shares at $2.72 ($814)
Page 26 of 77 · 1,525 filings